Manorama Industries (541974) Q4 22/23 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 22/23 earnings summary
22 Oct, 2026Executive summary
FY23 revenue from operations rose 26% YoY to Rs. 3,508 million; PAT increased 23% to Rs. 297.75 million, supported by product innovation, market expansion and operating efficiencies.
Q4 FY23 was described as the highest-ever quarterly performance, with revenue crossing Rs. 1,000 million.
Growth strategy centers on sustainable sourcing, customized specialty fats and butters, R&D, and expanded production capacity for food, confectionery and cosmetics customers.
Financial highlights
Revenue from operations was Rs. 3,508.0 million versus Rs. 2,791.2 million in FY22, up 26% YoY; total revenue including other income was Rs. 3,569.2 million.
EBITDA reached Rs. 564.5 million, up 45% YoY; EBITDA margin was 16.1% versus 14.0% in FY22.
PAT was Rs. 297.75 million versus Rs. 241.5 million, up 23%; PAT margin was 8.5% versus 8.7%.
Basic EPS was Rs. 24.98 and diluted EPS Rs. 24.97, compared with Rs. 20.76 for both in FY22.
Operating cash flow was Rs. 592.8 million versus cash used of Rs. 333.6 million in FY22; investing cash outflow was Rs. 994.7 million.
Outlook and guidance
The 25,000-tonne fractionation plant was expected to become operational in H1 FY24, followed by a gradual ramp-up; expanded capacity is expected to support throughput and revenue and profit growth.
A 300-TPD solvent extraction plant, warehouse and storage projects, refinery automation and packaging capacity expansion form part of the capacity and efficiency program.
Global specialty fats and butter demand is projected to grow at 7.71% CAGR through 2028; expansion and new geographies are intended to address the demand-supply gap.
Growth opportunities include Russia and Latin America, premium and artisanal chocolate, organic cosmetics, and demand for healthier, natural and customized ingredients.
Latest events from Manorama Industries
- Strong Q2/H1 growth and exports support phased expansion despite margin and cash-flow pressures.541974
Q2 26/27 - Manufacturing growth and capacity investment offset the exit from trading.541974
Q4 18/19 - Revenue rose 37.8% and PAT 65.6% as expansion targets global specialty-fat demand.541974
Q4 21/22 - FY20 sales rose 84% as a new plant expanded capacity amid pandemic disruption.541974
Q4 19/20 - Revenue advanced, but pandemic pressure cut profit as capacity expansion continued.541974
Q4 20/21 - Q1 FY27 revenue and profit surged, supported by global expansion, capex, and strong margins.541974
Q1 26/27 - Revenue up 76.1%, EBITDA up 92.5%, and major CapEx and expansion plans approved.541974
Q4 25/26 - Record Q3 FY25 revenue and profit, strong margins, and global expansion with new subsidiaries.541974
Q3 24/25 - H1 FY26 revenue and profit surged YoY, margins remained strong, and FY26 guidance was upgraded.541974
Q2 25/26